Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan

Published on Feb 1, 2019in International Journal of Urology3.369
· DOI :10.1111/IJU.13830
Ken-ichi Harada18
Estimated H-index: 18
(Kobe University),
Masahiro Nozawa14
Estimated H-index: 14
(Kindai University)
+ 13 AuthorsHirotsugu Uemura36
Estimated H-index: 36
(Kindai University)
Sources
Abstract
OBJECTIVES: To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carcinoma in the molecular target therapy era in Japan. METHODS: A multicenter, retrospective medical chart review study was carried out. Patients diagnosed with unresectable or metastatic renal cell carcinoma between January 2012 and August 2015 were enrolled. Data extracted from medical records included treatment duration, grade ≥3 adverse events, reason for discontinuation for each targeted therapy and survival data until August 2016. RESULTS: Of 277 eligible patients, 266, 170 and 77 received first-, second- and third-line systemic treatment, respectively. Tyrosine kinase inhibitors were the most common first-line therapy (72.2%), followed by mammalian target of rapamycin inhibitors (14.3%) and cytokines (13.5%). Among 170 patients who received second-line treatment, tyrosine kinase inhibitor-tyrosine kinase inhibitor was the most common sequence (58.8%), followed by tyrosine kinase inhibitor-mammalian target of rapamycin inhibitor (14.1%) and cytokine-tyrosine kinase inhibitor (14.1%). With a median follow-up period of 19.8 months, median overall survival was not reached at 48 months. Patients who discontinued first-line tyrosine kinase inhibitors in <6 months showed poorer overall survival compared with patients who received first-line tyrosine kinase inhibitors for ≥6 months. CONCLUSIONS: The present analysis illustrates the contemporary treatment patterns and prognosis for patients with unresectable or metastatic renal cancer in a real-world setting in Japan. Tyrosine kinase inhibitor-tyrosine kinase inhibitor represents the most commonly used sequence. Shorter treatment duration of first-line tyrosine kinase inhibitors is associated with poorer prognosis, suggesting the need for better treatment options.
📖 Papers frequently viewed together
21 Authors (Sei Naito, ..., Senji Hoshi)
References18
Newest
#4K. Bensalah (University of Rennes)H-Index: 48
#8Milan Hora (Charles University in Prague)H-Index: 15
The randomised phase III clinical trial Checkmate-214 showed a survival superiority for the combination of ipilimumab and nivolumab when compared with the previous standard of care in first-line metastatic/advanced clear cell renal cell carcinoma (RCC) (Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naive advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. LBA5, ES...
Source
#1Yoshihiko Tomita (Niigata University)H-Index: 31
#2Satoshi FukasawaH-Index: 15
Last. Seiichiro Ozono (Hamamatsu University)H-Index: 34
view all 15 authors...
Background: Nivolumab improved overall survival (OS) and objective response rate (ORR) versus everolimus in previously treated patients with advanced renal cell carcinoma in the phase III CheckMate 025 study (minimum follow-up: 14 months). We report efficacy and safety in the global and Japanese populations (minimum follow-up: 26 months). Methods: Patients were randomized 1:1 to receive nivolumab 3 mg/kg intravenously every 2 weeks or everolimus 10-mg tablet orally once daily. Primary endpoint: ...
Source
: The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These guidelines are developed by a multidisciplinary panel of leading experts from NCCN Member Institutions consisting of medical oncologists, hematologists and hematologic oncologists, radiation oncologists, urologists, and pathologists. The NCCN Guidelines are in continuous evolution and are updated annually or sometimes ...
Source
#1Mototsugu Oya (Keio: Keio University)H-Index: 56
#2Yoshihiko Tomita (YU: Yamagata University)H-Index: 28
Last. Hirotsugu Uemura (Kindai University)H-Index: 36
view all 11 authors...
Summary Subgroup analyses of a randomized global phase II study of axitinib showed objective response rate of 66% and median progression-free survival of 27.6 months in treatment-naive Japanese patients with metastatic renal cell carcinoma (RCC). This analysis evaluated overall survival (OS) and updated safety in 44 Japanese patients and compared with 169 non-Japanese patients. In addition, baseline characteristics for predictive factors that may influence OS in first-line metastatic RCC were ex...
Source
#1Ryuichi Mizuno (Keio: Keio University)H-Index: 22
#2Akira Miyajima (Keio: Keio University)H-Index: 29
Last. Mototsugu Oya (Keio: Keio University)H-Index: 56
view all 8 authors...
The aim of this study was to evaluate the clinical significance of visceral fat accumulation as a prognostic factor in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapies. A total of 114 patients were retrospectively reviewed. All patients received systemic therapy for mRCC at Keio University hospital in Japan. The intra-abdominal visceral fat area was determined by computed tomography at the umbilical level. The visceral fat accumulation was defined as ≥100 cm2....
Source
#1Yoshihiko Tomita (YU: Yamagata University)H-Index: 28
#2Satoshi FukasawaH-Index: 15
Last. Hideyuki Akaza (UTokyo: University of Tokyo)H-Index: 67
view all 12 authors...
OBJECTIVES: To conduct Japanese subgroup analyses of a randomized, global Phase II study of axitinib with and without dose titration in first-line metastatic renal cell carcinoma and to explore predictive factors for axitinib efficacy in first-line metastatic renal cell carcinoma. METHODS: The data included 44 Japanese and 169 non-Japanese treatment-naive patients with metastatic renal cell carcinoma. Patients received twice-daily axitinib 5 mg during a 4-week lead-in period. Patients who met th...
Source
#1Laurence Albiges (Université Paris-Saclay)H-Index: 61
#2A. Ari Hakimi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 51
Last. Georg A. BjarnasonH-Index: 55
view all 30 authors...
PurposeObesity is an established risk factor for clear cell renal cell carcinoma (RCC); however, some reports suggest that RCC developing in obese patients may be more indolent. We investigated the clinical and biologic effect of body mass index (BMI) on treatment outcomes in patients with metastatic RCC.MethodsThe impact of BMI (high BMI: ≥ 25 kg/m2 v low BMI: < 25 kg/m2) on overall survival (OS) and treatment outcome with targeted therapy was investigated in 1,975 patients from the Internation...
Source
#1Yoshihisa Kawai (Yamaguchi University)H-Index: 13
#2T OsawaH-Index: 1
Last. Hideyasu MatsuyamaH-Index: 30
view all 11 authors...
Factors predictive of survival have been identified in Western patients with metastatic clear cell renal cell carcinoma (mCCRCC) treated with sunitinib. Less is known, however, about factors predictive of survival in Japanese patients. This study evaluated factors prognostic of survival in Japanese patients with mCCRCC treated with first-line sunitinib.This retrospective study evaluated 46 consecutive Japanese mCCRCC patients treated with sunitinib as first line therapy. Clinical and biochemical...
Source
The Japan Cancer Surveillance Research Group aimed to estimate the cancer incidence in Japan in 2009 based on data collected from 32 of 37 population-based cancer registries, as part of the Monitoring of Cancer Incidence in Japan (MCIJ) project. The incidence of only primary invasive cancer in Japan for 2009 was estimated to be 775 601. Stomach cancer and breast cancer were the leading types of cancer in males and females, respectively.
Source
#1Daphne Day (Royal Melbourne Hospital)H-Index: 6
#2Yada Kanjanapan (Canberra Hospital)H-Index: 9
Last. Ben Tran (University of Melbourne)H-Index: 19
view all 13 authors...
Objective To examine the patterns of care and outcomes for metastatic renal cell carcinoma (mRCC) in Australia, where there are limited reimbursed treatment options. In particular, we aim to explore prescribing patterns for first-line systemic treatment, the practice of an initial watchful-waiting approach, and the use of systemic treatments in elderly patients. Subjects/Patients and Methods Patients with mRCC undergoing treatment between 2006 and 2012 were identified from four academic hospital...
Source
Cited By15
Newest
#1Yoshihiko Tomita (Niigata University)H-Index: 31
#2Go Kimura (Nippon Medical School)H-Index: 19
Last. Mototsugu Oya (Keio: Keio University)H-Index: 56
view all 10 authors...
BACKGROUND We performed subgroup analyses of the AFTER I-O study to clarify the association of time-to-treatment failure (TTF) and discontinuation reason of prior immune-oncology (I-O) therapy, and molecular targeted therapy (TT) regimen with the outcomes of TT after I-O. METHODS The data of Japanese metastatic renal cell carcinoma patients treated with TT after nivolumab (NIVO) (CheckMate 025) or NIVO + ipilimumab (IPI) (CheckMate 214) were retrospectively analyzed. The objective response rates...
Source
#2Bianka DarvalicsH-Index: 5
Last. Emmanuelle Boutmy (MSD: Merck & Co.)
view all 12 authors...
Source
#1Motohide Uemura (Osaka University)H-Index: 28
#2Noboru Nakaigawa (YCU: Yokohama City University)H-Index: 27
Last. Tamaki Fukuyama (Chugai Pharmaceutical Co.)H-Index: 2
view all 14 authors...
BACKGROUND Programmed death-ligand 1 (PD-L1) positivity is associated with poor prognosis in renal cell carcinoma (RCC). Because the prognostic impact and effect of confounding factors are less known, we investigated the prognostic significance of PD-L1 expression in Japanese patients with recurrent/metastatic RCC who started systemic therapy in 2010-2015. METHODS This multicenter, retrospective study recruited patients from 29 Japanese study sites who had prior systemic therapy for RCC (Novembe...
Source
#1Yoshihiko Tomita (Niigata University)H-Index: 31
#2Go Kimura (Nippon Medical School)H-Index: 19
Last. Mototsugu Oya (Keio: Keio University)H-Index: 56
view all 10 authors...
OBJECTIVES Guidelines for treatment of mRCC recommend nivolumab monotherapy (NIVO) for treated patients, and nivolumab plus ipilimumab combination therapy (NIVO+IPI) for untreated IMDC intermediate and poor-risk mRCC patients. Although molecular-targeted therapies (TTs) such as VEGFR-TKIs and mTORi are recommended as subsequent therapy after NIVO or NIVO+IPI, their efficacy and safety remain unclear. METHODS Outcome of Japanese patients with mRCC who received TT after NIVO (CheckMate 025) or NIV...
Source
#1Shingo Hatakeyama (Hirosaki University)H-Index: 28
#2Sei Naito (YU: Yamagata University)H-Index: 14
Last. Chikara Ohyama (Hirosaki University)H-Index: 43
view all 17 authors...
Objectives To compare overall survival between patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy and those not treated by cytoreductive nephrectomy. Methods We retrospectively evaluated 278 patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors between January 2008 and November 2019. Patients were divided into two groups: a cytoreductive nephrectomy group (immediate or deferred cytoreductive nephrectomy) and a group who r...
Source
#1Jianxin Xue (Nanjing Medical University)H-Index: 4
#2Wensun Chen (Nanjing Medical University)H-Index: 1
Last. Zengjun Wang (Nanjing Medical University)H-Index: 21
view all 7 authors...
We developed this study to describe the patterns of distant metastasis (DM) and explore the predictive and prognostic factors of DM in clear cell renal cell carcinoma (ccRCC) patients. We collected the eligible patients from the Surveillance, Epidemiology, and End Result (SEER) database from 2010 to 2015. Then, comparisons of baseline characteristics between patients in different metastatic patterns were made. In addition, proportional mortality ratios (PMRs) and proportion trends of different p...
Source
#1Koichi Kido (Hirosaki University)H-Index: 6
#2Shingo Hatakeyama (Hirosaki University)H-Index: 28
Last. Chikara Ohyama (Hirosaki University)H-Index: 43
view all 16 authors...
This study compared real-world outcomes of metastatic renal-cell carcinoma (mRCC) patients treated with tyrosine kinase inhibitors or nivolumab plus ipilimumab. Using the International mRCC Database Consortium (IMDC), we retrospectively evaluated intermediate- and poor-risk mRCC patients who were treated with nivolumab plus ipilimumab (Nivo-Ipi), tyrosine kinase inhibitors (TKIs) as the first-line therapy between August 2015 and January 2020. We compared oncological outcomes between the Nivo-Ipi...
Source
#1Toshikazu Tanaka (Hirosaki University)H-Index: 11
#2Shingo Hatakeyama (Hirosaki University)H-Index: 28
Last. Chikara Ohyama (Hirosaki University)H-Index: 43
view all 16 authors...
OBJECTIVES To investigate the efficacy and safety of first-line nivolumab plus ipilimumab for patients treated with metastatic renal cell carcinoma. METHODS We retrospectively evaluated 52 metastatic renal cell carcinoma patients who were treated with nivolumab plus ipilimumab between August 2015 and January 2020. Data on patient characteristics, treatment parameters and adverse events were obtained. Oncological outcomes were assessed according to the International Metastatic Renal Cell Carcinom...
Source
#1Nobuyuki Hinata (Kobe University)H-Index: 17
#2Junji YoneseH-Index: 27
Last. Hirotsugu Uemura (Kindai University)H-Index: 36
view all 20 authors...
BACKGROUND In a phase III clinical trial, CheckMate 025, treatment of metastatic renal cell carcinoma (mRCC) with nivolumab demonstrated superior efficacy over everolimus. However, as the clinical trial excluded patients with specific complications and poor performance status (PS), the effectiveness and safety of nivolumab in clinical practice, in which patients with various clinical complications are treated, is unclear. This study explored real-world nivolumab treatment in Japanese mRCC patien...
Source
#1Kazuyuki Numakura (Akita University)H-Index: 19
#2Mizuki Kobayashi (Akita University)H-Index: 1
Last. Tomonori Habuchi (Akita University)H-Index: 65
view all 19 authors...
PURPOSE: Despite nivolumab being increasingly used for treating metastatic renal cell carcinoma (mRCC), differing findings have been reported about its efficacy and safety in elderly patients. Thus, this study was aimed at evaluating nivolumab's efficacy and safety for treating mRCC in Japanese patients aged ≥ 75 years. METHODS: From March 2013 to August 2019, 118 mRCC patients (89 men and 29 women) were treated with nivolumab. The objective response rates (ORRs) were compared between patients a...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.